Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.

NCT03809988 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT03809988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03809988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
April 5, 2019
Completion date
November 30, 2022
Enrollment
198 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, hormone receptor positive tumor, human epidermal growth factor 2 negative carcinoma of breast